Arch Therapeutics Provides Year End Operational Update
09 nov. 2023 06h50 HE
|
Arch Therapeutics, Inc.
Fiscal year-end AC5 Advanced Wound System update includes Q4 record monthly order volumes, favorable reimbursement decisions and increases in paid claims.
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
02 nov. 2023 06h50 HE
|
Arch Therapeutics, Inc.
Arch Therapeutic's AC5 Advanced Wound System for chronic and acute surgical wounds to be featured at 2023 SAWC Fall.
Arch Therapeutics Provides AC5® Commercialization Update
13 sept. 2023 06h45 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Completes Financing as Bridge to Uplisting
07 sept. 2023 19h14 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
25 avr. 2023 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
05 avr. 2023 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
09 mars 2023 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
07 mars 2023 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
18 janv. 2023 07h35 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
17 janv. 2023 16h05 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical...